Alumis vs Roivant Sciences
Alumis is the larger business, with $24.1m of revenue in fiscal 2025 against $8.3m for Roivant Sciences (2.9 times as much). Alumis kept more of each dollar of sales as profit: a net margin of -1011.7% against -3629.2%. Alumis carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AlumisALMS, 2025 | Roivant SciencesROIV, 2026 |
|---|---|---|
| Revenue | $24.1m | $8.3m |
| Revenue growth | — | -71.6% |
| Net income | −$243m | −$300m |
| Operating margin | -1886.9% | -6235.7% |
| Net margin | -1011.7% | -3629.2% |
| Return on equity | -80.8% | -6.5% |
| Free cash flow | −$370m | −$759m |
| Cash | $89.7m | $1.42bn |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $17,000 | — |
| Employees | — | 721 |
| Market value | $829m | $26.20bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 39 buys, 9 sales | 1 buys, 117 sales |